结节病的发病机制与临床治疗研究进展

doi:10.3969/j.issn.1674-8115.2022.07.013

摘要/Abstract

摘要：

结节病可累及全身多个重要脏器，导致器官功能不可逆损害，其发病机制至今仍未明确。目前的研究认为结节病是一个多因素导致的疾病，易感基因可能构成遗传本底，病原体感染、自身抗原不耐受、无机物接触等因素可诱发疾病的发生。这些致病抗原暴露后，模式识别受体、抗原呈递、吞噬与自噬等免疫和炎症相关通路的异常导致巨噬细胞功能改变，CD4⁺T细胞过度激活，Th1和Th17亚群分泌大量白介素（interleukin，IL）-12、干扰素γ、肿瘤坏死因子α、IL-17和IL-23等细胞因子，诱导巨噬细胞聚集融合并形成肉芽肿，产生持续炎症。文章主要对结节病的发病机制相关研究作一综合阐述，并总结目前的临床治疗进展。

关键词: 结节病, 肉芽肿性炎症, 发病机制, 治疗

Abstract:

Sarcoidosis is a systemic disease which could affect many crucial organs and eventually cause irreversible functional damage to these organs. However, the pathogenesis of sarcoidosis is still not clear. Current studies suggest that sarcoidosis is caused by multiple factors. Individuals with certain genetic variations are highly susceptible to certain types of sarcoidosis. Furthermore, exposure to extrinsic antigenic factors such as pathogens or inorganic factors and intolerance of self-antigens also play a crucial role in the pathogenesis of sarcoidosis. Subsequent to antigenic stimulation, abnormality in pathways of pattern recognition receptor, phagosome or autophagy stimulates the activity of CD4⁺ T cells which release inflammatory cytokines such as interleukin (IL)-12, interferon-γ, tumor necrosis factor-α, IL-17, and IL-23, thus fostering the proliferation of Th1 and Th17 subpopulation and inducing the fusion of macrophages to form granulomas. Here we aim to review mechanistic studies in the past decade and list current therapeutic methods to provide some insights into the etiology, pathogenesis and management of sarcoidosis.

Key words: sarcoidosis, granulomatous inflammation, pathogenesis, treatment

中图分类号:

R593.9

张琳程, 钟华. 结节病的发病机制与临床治疗研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(7): 931-938.

ZHANG Lincheng, ZHONG Hua. Progress in pathogenesis and clinical treatment of sarcoidosis[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(7): 931-938.

参考文献 80

1	GRUNEWALD J, GRUTTERS J C, ARKEMA E V, et al. Publisher correction: sarcoidosis[J]. Nat Rev Dis Primers, 2019, 5(1): 49.
2	CROUSER E D, MAIER L A, WILSON K C, et al. Diagnosis and detection of sarcoidosis. an official American thoracic society clinical practice guideline[J]. Am J Respir Crit Care Med, 2020, 201(8): e26-e51.
3	SWIGRIS J J, OLSON A L, HUIE T J, et al. Sarcoidosis-related mortality in the United States from 1988 to 2007[J]. Am J Respir Crit Care Med, 2011, 183(11): 1524-1530.
4	OSWALD-RICHTER K A, BEACHBOARD D C, SEELEY E H, et al. Dual analysis for Mycobacteria and propionibacteria in sarcoidosis BAL[J]. J Clin Immunol, 2012, 32(5): 1129-1140.
5	CARLISLE J, EVANS W, HAJIZADEH R, et al. Multiple Mycobacterium antigens induce interferon-gamma production from sarcoidosis peripheral blood mononuclear cells[J]. Clin Exp Immunol, 2007, 150(3): 460-468.
6	DRAKE W P, DHASON M S, NADAF M, et al. Cellular recognition of Mycobacterium tuberculosis ESAT-6 and KatG peptides in systemic sarcoidosis[J]. Infect Immun, 2007, 75(1): 527-530.
7	DRAKE W P, CULVER D A, BAUGHMAN R P, et al. Phase II investigation of the efficacy of antimycobacterial therapy in chronic pulmonary sarcoidosis[J]. Chest, 2021, 159(5): 1902-1912.
8	INAOKA P T, SHONO M, KAMADA M, et al. Host-microbe interactions in the pathogenesis and clinical course of sarcoidosis[J]. J Biomed Sci, 2019, 26(1): 45.
9	CLARKE E L, LAUDER A P, HOFSTAEDTER C E, et al. Microbial lineages in sarcoidosis. A metagenomic analysis tailored for low-microbial content samples[J]. Am J Respir Crit Care Med, 2018, 197(2): 225-234.
10	KAISER Y, EKLUND A, GRUNEWALD J. Moving target: shifting the focus to pulmonary sarcoidosis as an autoimmune spectrum disorder[J]. Eur Respir J, 2019, 54(1): 1802153.
11	WANG S H, CHUNG C H, HUANG T W, et al. Bidirectional association between tuberculosis and sarcoidosis[J]. Respirol Carlton Vic, 2019, 24(5): 467-474.
12	BERLIN M, FOGDELL-HAHN A, OLERUP O, et al. HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis[J]. Am J Respir Crit Care Med, 1997, 156(5): 1601-1605.
13	WENNERSTRÖM A, PIETINALHO A, LASOTA J, et al. Major histocompatibility complex class II and BTNL2 associations in sarcoidosis[J]. Eur Respir J, 2013, 42(2): 550-553.
14	CALENDER A, WEICHHART T, VALEYRE D, et al. Current insights in genetics of sarcoidosis: functional and clinical impacts[J]. J Clin Med, 2020, 9(8): E2633.
15	WAHLSTRÖM J, DENGJEL J, PERSSON B, et al. Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis[J]. J Clin Invest, 2007, 117(11): 3576-3582.
16	WAHLSTRÖM J, DENGJEL J, WINQVIST O, et al. Autoimmune T cell responses to antigenic peptides presented by bronchoalveolar lavage cell HLA-DR molecules in sarcoidosis[J]. Clin Immunol, 2009, 133(3): 353-363.
17	GRUNEWALD J, KAISER Y, OSTADKARAMPOUR M, et al. T-cell receptor-HLA-DRB1 associations suggest specific antigens in pulmonary sarcoidosis[J]. Eur Respir J, 2016, 47(3): 898-909.
18	KINLOCH AJ, KAISER Y, WOLFGEHER D, et al. In situ humoral immunity to vimentin in HLA-DRB1*03 + patients with pulmonary sarcoidosis[J]. Front Immunol, 2018, 9: 1516.
19	SHARMA O P. Sarcoidosis and other autoimmune disorders[J]. Curr Opin Pulm Med, 2002, 8(5): 452-456.
20	STARSHINOVA A A, MALKOVA A M, BASANTSOVA N Y, et al. Sarcoidosis as an autoimmune disease[J]. Front Immunol, 2019, 10: 2933.
21	GREAVES S A, ATIF S M, FONTENOT A P. Adaptive immunity in pulmonary sarcoidosis and chronic beryllium disease[J]. Front Immunol, 2020, 11: 474.
22	MÜLLER-QUERNHEIM J, GAEDE K I, FIREMAN E, et al. Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients[J]. Eur Respir J, 2006, 27(6): 1190-1195.
23	FIREMAN E, HAIMSKY E, NOIDERFER M, et al. Misdiagnosis of sarcoidosis in patients with chronic beryllium disease[J]. Sarcoidosis Vasc Diffuse Lung Dis, 2003, 20(2): 144-148.
24	BALMES J R, ABRAHAM J L, DWEIK R A, et al. An official American thoracic society statement: diagnosis and management of beryllium sensitivity and chronic beryllium disease[J]. Am J Respir Crit Care Med, 2014, 190(10): e34-e59.
25	BEIJER E, MEEK B, BOSSUYT X, et al. Immunoreactivity to metal and silica associates with sarcoidosis in Dutch patients[J]. Respir Res, 2020, 21(1): 141.
26	BEIJER E, KRAAIJVANGER R, ROODENBURG C, et al. Simultaneous testing of immunological sensitization to multiple antigens in sarcoidosis reveals an association with inorganic antigens specifically related to a fibrotic phenotype[J]. Clin Exp Immunol, 2021, 203(1): 115-124.
27	CLAYTON G M, WANG Y, CRAWFORD F, et al. Structural basis of chronic beryllium disease: linking allergic hypersensitivity and autoimmunity[J]. Cell, 2014, 158(1): 132-142.
28	MORTAZ E, ADCOCK I M, ABEDINI A, et al. The role of pattern recognition receptors in lung sarcoidosis[J]. Eur J Pharmacol, 2017, 808: 44-48.
29	PACHECO Y, LIM C X, WEICHHART T, et al. Sarcoidosis and the mTOR, Rac1, and autophagy triad[J]. Trends Immunol, 2020, 41(4): 286-299.
30	SCHNERCH J, PRASSE A, VLACHAKIS D, et al. Functional toll-like receptor 9 expression and CXCR3 ligand release in pulmonary sarcoidosis[J]. Am J Respir Cell Mol Biol, 2016, 55(5): 749-757.
31	VELTKAMP M, VAN MOORSEL C H M, RIJKERS G T, et al. Toll-like receptor (TLR)-9 genetics and function in sarcoidosis[J]. Clin Exp Immunol, 2010, 162(1): 68-74.
32	PABST S, BRADLER O, GILLISSEN A, et al. Toll-like receptor-9 polymorphisms in sarcoidosis and chronic obstructive pulmonary disease[J]. Adv Exp Med Biol, 2013, 756: 239-245.
33	WIKÉN M, GRUNEWALD J, EKLUND A, et al. Higher monocyte expression of TLR2 and TLR4, and enhanced pro-inflammatory synergy of TLR2 with NOD2 stimulation in sarcoidosis[J]. J Clin Immunol, 2009, 29(1): 78-89.
34	CHEN E S, SONG Z M, WILLETT M H, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through toll-like receptor-2[J]. Am J Respir Crit Care Med, 2010, 181(4): 360-373.
35	CHEN X Q, ZHAO D P, NING Y, et al. Toll-like receptors 2 expression in mediastinal lymph node of patients with sarcoidosis[J]. Ann Transl Med, 2020, 8(18): 1182.
36	LINKE M, PHAM H T T, KATHOLNIG K, et al. Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression[J]. Nat Immunol, 2017, 18(3): 293-302.
37	CALENDER A, ROLLAT FARNIER P A, BUISSON A, et al. Whole exome sequencing in three families segregating a pediatric case of sarcoidosis[J]. BMC Med Genomics, 2018, 11(1): 23.
38	BESNARD V, CALENDER A, BOUVRY D, et al. G908R NOD2 variant in a family with sarcoidosis[J]. Respir Res, 2018, 19(1): 44.
39	KISHORE A, PETERSEN B S, NUTSUA M, et al. Whole-exome sequencing identifies rare genetic variations in German families with pulmonary sarcoidosis[J]. Hum Genet, 2018, 137(9): 705-716.
40	CROUSER E D, LOCKE L W, JULIAN M W, et al. Phagosome-regulated mTOR signalling during sarcoidosis granuloma biogenesis[J]. Eur Respir J, 2021, 57(3): 2002695.
41	BROOS C E, VAN NIMWEGEN M, HOOGSTEDEN H C, et al. Granuloma formation in pulmonary sarcoidosis[J]. Front Immunol, 2013, 4: 437.
42	OTA M, AMAKAWA R, UEHIRA K, et al. Involvement of dendritic cells in sarcoidosis[J]. Thorax, 2004, 59(5): 408-413.
43	LIU H, JAKUBZICK C, OSTERBURG A R, et al. Dendritic cell trafficking and function in rare lung diseases[J]. Am J Respir Cell Mol Biol, 2017, 57(4): 393-402.
44	ZABA L C, SMITH G P, SANCHEZ M, et al. Dendritic cells in the pathogenesis of sarcoidosis[J]. Am J Respir Cell Mol Biol, 2010, 42(1): 32-39.
45	TEN BERGE B, KLEINJAN A, MUSKENS F, et al. Evidence for local dendritic cell activation in pulmonary sarcoidosis[J]. Respir Res, 2012, 13: 33.
46	MOLLER D R, FORMAN J D, LIU M C, et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis[J]. J Immunol, 1996, 156(12): 4952-4960.
47	PRASSE A, GEORGES C G, BILLER H, et al. Th1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4⁺ and CD8⁺ T cells[J]. Clin Exp Immunol, 2000, 122(2): 241-248.
48	KATCHAR K, EKLUND A, GRUNEWALD J. Expression of Th1 markers by lung accumulated T cells in pulmonary sarcoidosis[J]. J Intern Med, 2003, 254(6): 564-571.
49	FACCO M, CABRELLE A, TERAMO A, et al. Sarcoidosis is a Th1/Th17 multisystem disorder[J]. Thorax, 2011, 66(2): 144-150.
50	OSTADKARAMPOUR M, EKLUND A, MOLLER D, et al. Higher levels of interleukin IL-17 and antigen-specific IL-17 responses in pulmonary sarcoidosis patients with Löfgren's syndrome[J]. Clin Exp Immunol, 2014, 178(2): 342-352.
51	RAMSTEIN J, BROOS C E, SIMPSON L J, et al. IFN-γ-producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells[J]. Am J Respir Crit Care Med, 2016, 193(11): 1281-1291.
52	LEXBERG M H, TAUBNER A, ALBRECHT I, et al. IFN-γ and IL-12 synergize to convert in vivo generated Th17 into Th1/Th17 cells[J]. Eur J Immunol, 2010, 40(11): 3017-3027.
53	MIEDEMA J R, KAISER Y, BROOS C E, et al. Th17-lineage cells in pulmonary sarcoidosis and Löfgren's syndrome: friend or foe? [J]. J Autoimmun, 2018, 87: 82-96.
54	BROOS C E, KOTH L L, VAN NIMWEGEN M, et al. Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes[J]. Eur Respir J, 2018, 51(3): 1701124.
55	KAISER Y, LEPZIEN R, KULLBERG S, et al. Expanded lung T-bet⁺RORγT⁺ CD4⁺ T-cells in sarcoidosis patients with a favourable disease phenotype[J]. Eur Respir J, 2016, 48(2): 484-494.
56	SAKTHIVEL P, GRUNEWALD J, EKLUND A, et al. Pulmonary sarcoidosis is associated with high-level inducible co-stimulator (ICOS) expression on lung regulatory T cells: possible implications for the ICOS/ICOS-ligand axis in disease course and resolution[J]. Clin Exp Immunol, 2016, 183(2): 294-306.
57	IDALI F, WIKÉN M, WAHLSTRÖM J, et al. Reduced Th1 response in the lungs of HLA-DRB1*0301 patients with pulmonary sarcoidosis[J]. Eur Respir J, 2006, 27(3): 451-459.
58	BROOS C E, VAN NIMWEGEN M, IN 'T VEEN J C C M, et al. Decreased cytotoxic T-lymphocyte antigen 4 expression on regulatory T cells and Th17 cells in sarcoidosis: double trouble? [J]. Am J Respir Crit Care Med, 2015, 192(6): 763-765.
59	BROOS C E, VAN NIMWEGEN M, KLEINJAN A, et al. Impaired survival of regulatory T cells in pulmonary sarcoidosis[J]. Respir Res, 2015, 16: 108.
60	SPAGNOLO P, ROSSI G, TRISOLINI R, et al. Pulmonary sarcoidosis[J]. Lancet Respir Med, 2018, 6(5): 389-402.
61	Interstitial Lung Disease Group CTSCMA, Chinese Association of Chest Physicians Interstitial Lung Disease Working Committee. Chinese expert consensus on the diagnosis and treatment of pulmonary sarcoidosis[J]. Zhonghua Jie Hu Xi Za Zhi, 2019, 42(9): 685-693.
62	ISRAEL H L, FOUTS D W, BEGGS R A. A controlled trial of prednisone treatment of sarcoidosis[J]. Am Rev Respir Dis, 1973, 107(4): 609-614.
63	BROOS C E, POELL L H C, LOOMAN C W N, et al. No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis[J]. Respir Med, 2018, 138S: S31-S37.
64	VORSELAARS A D M, WUYTS W A, VORSELAARS V M M, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis[J]. Chest, 2013, 144(3): 805-812.
65	HAMZEH N, VOELKER A, FORSSÉN A, et al. Efficacy of mycophenolate mofetil in sarcoidosis[J]. Respir Med, 2014, 108(11): 1663-1669.
66	ANTONIU S A. Targeting the TNF-alpha pathway in sarcoidosis[J]. Expert Opin Ther Targets, 2010, 14(1): 21-29.
67	BAUGHMAN R P, DRENT M, KAVURU M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement[J]. Am J Respir Crit Care Med, 2006, 174(7): 795-802.
68	CHAPELON-ABRIC C, SAADOUN D, BIARD L, et al. Long-term outcome of infliximab in severe chronic and refractory systemic sarcoidosis: a report of 16 cases[J]. Clin Exp Rheumatol, 2015, 33(4): 509-515.
69	RUSSELL E, LUK F, MANOCHA S, et al. Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy[J]. Semin Arthritis Rheum, 2013, 43(1): 119-124.
70	KULLBERG S, RIVERA N V, ABO AL HAYJA M, et al. Changes in lung immune cells related to clinical outcome during treatment with infliximab for sarcoidosis[J]. Clin Exp Immunol, 2020, 201(1): 85-93.
71	DAI C, SHIH S, ANSARI A, et al. Biologic therapy in the treatment of cutaneous sarcoidosis: a literature review[J]. Am J Clin Dermatol, 2019, 20(3): 409-422.
72	CROMMELIN H A, VAN DER BURG L M, VORSELAARS A D, et al. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab[J]. Respir Med, 2016, 115: 72-77.
73	GUPTA N, BLEESING J H, MCCORMACK F X. Successful response to treatment with sirolimus in pulmonary sarcoidosis[J]. Am J Respir Crit Care Med, 2020, 202(9): e119-e120.
74	MANZIA T M, BELLINI M I, CORONA L, et al. Successful treatment of systemic de novo sarcoidosis with cyclosporine discontinuation and provision of rapamune after liver transplantation[J]. Transpl Int, 2011, 24(8): e69-e70.
75	FRYE B C, RUMP I C, UHLMANN A, et al. Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC)-protocol for a multi-center, single-arm phase Ⅱa trial[J]. Contemp Clin Trials Commun, 2020, 19: 100575.
76	LEE N S, BARBER L, AKULA S M, et al. Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis[J]. Clin Vaccine Immunol, 2011, 18(8): 1306-1316.
77	SWEISS N J, LOWER E E, MIRSAEIDI M, et al. Rituximab in the treatment of refractory pulmonary sarcoidosis[J]. Eur Respir J, 2014, 43(5): 1525-1528.
78	VESELY N C, THOMAS R M, RUDNICK E, et al. Scar sarcoidosis following rituximab therapy[J]. Dermatol Ther, 2020, 33(6): e13693.
79	JUDSON M A, BAUGHMAN R P, COSTABEL U, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis[J]. Eur Respir J, 2014, 44(5): 1296-1307.
80	JULIAN M W, SHAO G H, SCHLESINGER L S, et al. Nicotine treatment improves Toll-like receptor 2 and Toll-like receptor 9 responsiveness in active pulmonary sarcoidosis[J]. Chest, 2013, 143(2): 461-470.

[1]	何冬梅, 杨驰. 下颌骨髁突骨折的诊治方案：基于上海交通大学医学院附属第九人民医院颞下颌关节中心的经验[J]. 上海交通大学学报（医学版）, 2022, 42(6): 695-701.
[2]	何冬梅, 杨驰. 颞下颌关节强直的诊治方案：基于上海交通大学医学院附属第九人民医院颞下颌关节中心的经验[J]. 上海交通大学学报（医学版）, 2022, 42(6): 702-708.
[3]	张善勇, 杨驰. 颞下颌关节骨关节炎的诊治方案：基于上海交通大学医学院附属第九人民医院颞下颌关节中心的经验[J]. 上海交通大学学报（医学版）, 2022, 42(6): 709-716.
[4]	成桢哲, 金晨曦, 冯宝怡, 郑晓飞, 刘祎晴, 吴皓, 陶永. 基于腺相关病毒血清型8型介导的Gjb2基因c.109G>A纯合突变耳聋小鼠的基因治疗[J]. 上海交通大学学报（医学版）, 2022, 42(6): 735-741.
[5]	金磊, 徐文彬, 叶晨静, 阎骅. 泊沙康唑对血液恶性肿瘤化疗患者的预防性抗真菌作用[J]. 上海交通大学学报（医学版）, 2022, 42(6): 792-796.
[6]	郑诗凡, 马皎. 肿瘤干细胞代谢在肿瘤发展中作用的研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(6): 825-832.
[7]	邓露, 李佳怡. 点阵CO₂激光治疗女性压力性尿失禁的研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(5): 685-689.
[8]	王衍鸿, 韩稷钰, 万大千. 下肢外骨骼机器人对关节镜下半月板修补术后患者功能重建的治疗效果[J]. 上海交通大学学报（医学版）, 2022, 42(3): 337-343.
[9]	林艳艳, 许岩, 李慧. 儿童急性淋巴细胞白血病化学治疗常规药物耐药机制的研究进展[J]. 上海交通大学学报(医学版), 2022, 42(2): 211-217.
[10]	邹弋华, 彭婕, 赵培泉. 先天性视盘凹陷性异常的临床特征与治疗研究进展[J]. 上海交通大学学报(医学版), 2022, 42(2): 230-234.
[11]	陈炜, 刘颖斌. 肝门部胆管癌综合治疗的进展与争议[J]. 上海交通大学学报(医学版), 2022, 42(1): 1-8.
[12]	张宇, 吴晓渊, 管丽华, 刘译远, 彭星月, 谢海燕, 胡玮, 郝可可, 夏宁, 陆国军, 侯志波. 高通量药物敏感性筛选系统在非小细胞肺癌伴恶性胸腔积液治疗中的应用[J]. 上海交通大学学报(医学版), 2022, 42(1): 82-89.
[13]	李莉莎, 李建辉, 何斌, 吴楠楠, 朱同玉, 郭晓奎, 陈峥宏. 噬菌体治疗泛耐药肺炎克雷伯菌肺部感染的临床应用及效果初探[J]. 上海交通大学学报(医学版), 2021, 41(9): 1272-1276.
[14]	熊雷, 易茜, 许明芳, 陈健. MRPL12在肺腺癌中的表达和预后分析[J]. 上海交通大学学报(医学版), 2021, 41(8): 1033-1040.
[15]	周珺珺, 赵洁, 汤静燕, 蒋马伟, 马秀梅, 白永瑞. Ⅲ~Ⅳ期神经母细胞瘤患儿放射治疗预后因素分析[J]. 上海交通大学学报(医学版), 2021, 41(8): 1051-1055.